Novartis AG (NVS) Shares Bought by John G Ullman & Associates Inc.
John G Ullman & Associates Inc. increased its position in Novartis AG (NYSE:NVS) by 34.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,110 shares of the company’s stock after acquiring an additional 40,720 shares during the period. Novartis AG makes up about 2.6% of John G Ullman & Associates Inc.’s investment portfolio, making the stock its 9th biggest position. John G Ullman & Associates Inc. owned approximately 6,683.74% of Novartis AG worth $13,574,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. City Holding Co. grew its holdings in shares of Novartis AG by 4.6% in the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after acquiring an additional 54 shares during the period. WFG Advisors LP grew its holdings in shares of Novartis AG by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after acquiring an additional 337 shares during the period. Cable Hill Partners LLC grew its holdings in shares of Novartis AG by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after acquiring an additional 1,107 shares during the period. Archford Capital Strategies LLC grew its holdings in shares of Novartis AG by 72.3% in the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after acquiring an additional 621 shares during the period. Finally, Kernodle & Katon Asset Management Group LLC grew its holdings in Novartis AG by 3.4% during the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares during the last quarter. Institutional investors and hedge funds own 10.94% of the company’s stock.
A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a report on Tuesday, September 19th. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a report on Wednesday, July 26th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a report on Tuesday, October 24th. Barclays PLC cut Novartis AG from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Finally, BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company. Novartis AG has an average rating of “Hold” and an average target price of $85.28.
Novartis AG (NYSE:NVS) traded down $0.97 during mid-day trading on Thursday, hitting $81.97. The stock had a trading volume of 785,179 shares, compared to its average volume of 2,397,176. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $194,901.38, a PE ratio of 17.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.72.
Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.04. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The business had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.21 billion. During the same quarter last year, the firm earned $1.23 earnings per share. The business’s revenue was up 2.4% on a year-over-year basis. sell-side analysts forecast that Novartis AG will post 4.75 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Novartis AG (NVS) Shares Bought by John G Ullman & Associates Inc.” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/09/novartis-ag-nvs-shares-bought-by-john-g-ullman-associates-inc.html.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.